Overview

Lung-MAP S1400K: c-MET Positive

Status:
Completed
Trial end date:
2021-07-30
Target enrollment:
Participant gender:
Summary
S1400K of Lung-MAP seeks to evaluate the overall response rate with ABBV-399 (Process II) in patients with c-MET positive SCCA. S1400K is a biomarker-driven study for patients with Stage IV or recurrent squamous cell lung cancer, who have c-MET positive squamous cell tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Southwest Oncology Group